Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is supported by a large, underpenetrated insulin-delivery market and a product portfolio that can drive multiple growth levers simultaneously, including the t:slim X2, the newly launched smaller Mobi pump, the planned Sigi tubeless patch pump, and continued Control-IQ automation enhancements. The company’s improving execution is reinforced by in-line revenue with gross margins that have exceeded consensus, full-year expectations of $1.065–$1.085B in revenue, 56–57% gross margin, and 5–6% EBITDA margin, while the pharmacy-channel shift should improve lifetime customer value to about $17K versus $8K from DME and support margin expansion over time. With roughly three-quarters of revenue from the US, over 150,000 OUS patients representing a potential $100M+ annual renewal opportunity, and Mobi Tubeless slated for a 2H’26 launch and late 2026 FDA approval timing, the company has a visible path to faster growth and a stronger profitability profile that appears underappreciated by the market.

Bears say

Tandem Diabetes Care is challenged by a business mix that still depends heavily on upfront durable-pump revenue even as it shifts to a Pay/Go model, creating near-term pressure from $0 upfront shipments and execution risk around converting patients into the pharmacy channel, where management itself notes the economics are better but adoption is still early. The bearish case is further supported by the company’s relatively modest scale and profitability profile, with the stock cited at just 1.3x EV/Sales and implied 2026-2030 margins still below the more optimistic long-term goals, which leaves downside if growth or pricing benefits fail to materialize as expected. Although record Q2 pump shipments of 22K, 10% of U.S. sales through pharmacy, and 45% formulary coverage show momentum, the market still appears to be underestimating the risk that the transition temporarily suppresses revenue before benefits from recurring supplies, international renewals, and new products like Mobi Tubeless are fully realized.

TNDM has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 18 analysts, TNDM has a Buy consensus rating as of Oct 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.